Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No restrictions. I didn't want you to think I was directing my post towards you.
On the day I let Admin know of this problem I was asked for a link and replied right away.
Since then I have sent two PM's to Admin. asking for an update because the problem still exists. I have not gotten any reply or update and the problem still exists.
I invite anyone else to contact Admin regarding this problem.
My post was not directed to you.
Yes. You know how they read emails at the end of the show and a person asked if MDR was a buy and he said no and he was going to sell his by end of this year.
I do think that people do loss sight of just how much SOLI management has done in the last 12 months. Here are just some of the hightlights:
- became fully audited
- raised $ to acquire CareClix
- Acquired CareClix
- sued Greg M. and won and reduced OS bu 12.6 million shares
- got a sponsoring MM to file form 211
- got form 211 accepted and came off the Greys
- started CareClix revenue from $0 and grew it to $532k last Q
- got the CE removed
- built a IR website
- Signed a supper contract with MAXIS GBN
- Got CareClix SOC 2 Type 1 Audit Certification
Next steps:
- significantly grow the revenue
- move to OTCQB
Jon N. on CNBC just said its't not a buy and he will sell his by end of this year
Or until additional information is made available via a new PR or 8K which can be sooner than the 10K.
I guess you haven't really read ALL my posts regarding MAXIS GBN.
In all my posts I have said that we really don't know how big the revenue impact will be regarding this deal. We don't have the details yet.
Therefore, the deal hasn't had an impact on the PPS yet. How big the impact will be will be based on how big the revenue is impacted.
Mikeo56 I agree. One or two big contracts and we could see it.
And we might already have one with the 12/3 Pr: MAXIS GBN partners with CareClix as latest global wellness provider.
I am very interested in seeing what the revenue impact of this deal will be in the coming months.
premier1one was replying to my post regarding SOLI applying to OTCQB and then you replied to him in that thread...so it appeared your reply was regarding OTCQB. Get it?
Oh I thought it was in reference to the OTCQB.
What does 60 cents mean?
OTCQB: Today I re-read the requirements to qualify for the OTCQB. I wasn't sure how coming off the Greys or having a CE would impact SOLI's ability to apply so I called OTC Markets. SOLI couldn't apply to OTCQB with a CE on it, but as soon as the CE came off they could apply.
OTC Markets wouldn't tell me if SOLI has already applied to the OTCQB.
They did confirm that once a company does apply the review process is anywhere from a few weeks to a couple months.
I am hoping that SOLI has applied already.
I agree doogdilinger! I am looking forward to the next SOLI contract (or) acquisition.
It is Edf's post which sited the PR
EdF Member Level Friday, 12/13/19 12:32:11 PM
Re: None 0
Post #
34989
of 35004
My favorite part from the last PR. Boy the potential is massive with CareClix. Let's see them bring it all together. If they can, we are going to someday wish we bought every share under a dollar.
https://irdirect.net/prviewer/release/id/4171528
Another 8K
ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.
On December 4, 2019, GEP Equity Holdings Limited (herein referred to as the “Seller”) a fully owned subsidiary of Argentum 47, Inc. entered into a legally binding stock purchase agreement with Quartal Financial Solutions AG (herein referred to as the “Purchaser”) a fully owned subsidiary of Quartal Financial Solutions Inc. In such agreement, the Seller agreed to sell to the Purchaser 227,100 common restricted shares of Quartal Financial Solutions Inc. for a total consideration of 170,325 Swiss Francs (equivalent to U.S.$170,100 at the date of the agreement).
On December 10, 2019, as per the agreement, the Purchaser wired the total consideration to our Attorney, Mr. David E. Wise, Esq., to be held in escrow.
On December 13, 2019, the beneficial ownership of the Quartal Financial Solutions Inc. common restricted shares was formally transferred from GEP Equity Holdings Limited to Quartal Financial Solutions AG and the total consideration was released to the Seller.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
1. On December 18, 2019, the Company and Xantis S.A. have agreed to formally enter into a new securitised receivable agreement with the assignment of receivables owned and to be owned by the subsidiary(ies) of the Company to Keyholder Three Securitisation Fund (to be renamed “Aegeus Securitisation Fund”), a Securitisation Fund established in Luxembourg under the Laws of 22 March 2004 regarding Securitisation and represented by Xantis S.A., the legally appointed fund management company of Keyholder Three Securitisation Fund (to be renamed “Aegeus Securitisation Fund”), with registered office at 75 Parc d’Activités, L-8308 Capellen, Grand-Duchy of Luxembourg, registered number B140689. The details of this new securitized agreement will be disclosed by the Company with the U.S. Securities and Exchange Commission (“SEC”) in a Form 8-K Current Report.
2. In accordance with the terms of the second addendum executed on November 8, 2019, the Company now agrees to defer the conversion of the Second Tranche under the Original Agreement that was received on October 10, 2018, for a further two (2) years and one (1) day from the date of execution of this addendum. In this case, the conversion price per share of the Second Tranche of the Original Agreement into equity of the Company will be equivalent to the closing market price two days prior the new conversion date.
3. The Parties agree that this deferral of the conversion of the Second Tranche of funding under the Original Agreement will only take legal effect if the Company receives sufficient evidence that the first loan amount agreed for an amount of, 250,000 GBP or approximately U.S.$329,100, is received.
4. The parties agree that the first tranche of the loan amount equating to 250.000 GBP will be wired to the escrow account of the Company´s U.S. Attorney, Mr. David E. Wise Esq., on December 16, 2019 to allow time for the new Loan Agreement and Receivable Assignment Agreement to be finalized and executed on December 18, 2019. Once the contracts are signed, the amount will be released from escrow to the Company. If the Company or its Attorney does not receive a confirmation of such wire transfer by December 16, 2019 and both the new Loan Agreement and Receivable Assignment Agreement are not fully executed and sent back to the Company by the close of business of December 18, 2019, then the Second Tranche will be immediately and unilaterally converted by the Company into equity of the Company at a conversion price of U.S.$0.02 per share as per the terms and conditions of the Original Agreement.
5. This third addendum to the June 6, 2018 funding agreement will be duly filed by the Company with the SEC via a respective Form 8-K Current Report.
8K out
ITEM 1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT.
On June 6, 2018, the Company entered into a funding agreement with Xantis S.A., a company incorporated under the laws of Luxembourg that is the legally appointed fund management company of Xantis Aion Securitisation Fund (“Fund”). This funding agreement was filed with the SEC as Exhibit 10.1 to a Form 8-K on June 11, 2018.
On October 10, 2018 the Company received U.S.$653,039.50 from the Fund relating to a second tranche of funding pertaining to the June 6, 2018 funding agreement. This second tranche of funding was due to be converted to equity of the Company at a rate of U.S.$0.02 per share on October 11, 2019.
On October 9, 2019, the Company and Xantis S.A. agreed and executed an addendum to the June 6, 2018 funding agreement with the following clauses:
1. Due to ongoing negotiations of a new funding agreement, the Company agrees to defer the conversion of the second tranche of the June 6, 2018 funding agreement for 30 calendar days from the date of execution of this addendum.
2. If the Fund and the Company cannot reach a consensus regarding the terms and conditions of the new funding agreement that satisfies both parties, the Company will automatically convert the second tranche of the June 6, 2018 funding agreement 30 calendar days from the date of execution of this addendum. This conversion into equity of the Company will be at U.S.$0.02 per share as per the terms and conditions of the June 6, 2018 funding agreement.
3. If the Fund and the Company are able to reach a consensus on the terms and conditions of the new funding agreement that satisfies both parties and a new agreement is effectively executed on or before the 30 day deadline, then the Company will defer the conversion of the second tranche of the June 10, 2018 funding agreement for a further two (2) years and one (1) day from the date of execution of this addendum. In this case the conversion price of the second tranche of the June 6, 2018 funding agreement into equity of the Company will be equivalent to the closing market price two days prior the new conversion date.
On November 8, 2019, the Company and Xantis S.A. agreed and executed a second addendum to the June 6, 2018 funding agreement with the following clauses:
1. Due to the ongoing negotiations of a new funding agreement, the Company agrees to once again defer the conversion of the second tranche of the June 6, 2018 funding agreement until Friday, December 13, 2019.
2. If the Fund and the Company are able to reach a consensus on the terms and conditions of a new funding agreement that satisfies both parties and a new agreement is effectively executed on or before the December 13, 2019 deadline for funding amounting to a minimum of 250,000 GBP (approximately U.S.$321,000) to be funded on or before this date as per the terms of the new agreement, then the Company will defer the conversion of the second tranche of the June 6, 2018 funding agreement for a further two (2) years and one (1) day from the date that the new funding agreement is fully executed. In this case, the conversion price of the second tranche of the June 6, 2018 funding agreement into common shares of the Company will be equivalent to the closing market price two days prior the new conversion date.
3. If the Fund and the Company cannot reach a consensus regarding the terms and conditions of the new funding agreement that satisfies both parties on or before December 13, 2019 and also the initial tranche amounting to a minimum of 250,000 GBP (approximately U.S.$321,000) is not effectively funded on or before this date, the Company will automatically convert the second tranche of the June 6, 2018 funding agreement on December 16, 2019. This conversion into common shares of the Company will be at a rate of U.S.$0.02 per share as per the terms and conditions of the June 6, 2018 funding agreement.
On December 13, 2019, the Company and Xantis S.A. agreed and executed a third and final addendum to the June 6, 2018 funding agreement with the following clauses:
1. On December 18, 2019, the Company and Xantis S.A. have agreed to formally enter into a new securitised receivable agreement with the assignment of receivables owned and to be owned by the subsidiary(ies) of the Company to Keyholder Three Securitisation Fund (to be renamed “Aegeus Securitisation Fund”), a Securitisation Fund established in Luxembourg under the Laws of 22 March 2004 regarding Securitisation and represented by Xantis S.A., the legally appointed fund management company of Keyholder Three Securitisation Fund (to be renamed “Aegeus Securitisation Fund”), with registered office at 75 Parc d’Activités, L-8308 Capellen, Grand-Duchy of Luxembourg, registered number B140689. The details of this new securitized agreement will be disclosed by the Company with the U.S. Securities and Exchange Commission (“SEC”) in a Form 8-K Current Report.
2. In accordance with the terms of the second addendum executed on November 8, 2019, the Company now agrees to defer the conversion of the Second Tranche under the June 6, 2018 agreement (“Original Agreement”) that was received on October 10, 2018, for a further two (2) years and one (1) day from the date of execution of this addendum. In this case, the conversion price per share of the Second Tranche of the Original Agreement into equity of the Company will be equivalent to the closing market price two days prior the new conversion date.
3. The Parties agree that this deferral of the conversion of the Second Tranche of funding under the Original Agreement will only take legal effect if the Company receives sufficient evidence that the first loan amount agreed for an amount of, 250,000 GBP or approximately U.S.$329,100, is received.
4. The parties agree that the first tranche of the loan amount equating to 250.000 GBP will be wired to the escrow account of the Company´s U.S. Attorney, Mr. David E. Wise Esq., on December 16, 2019 to allow time for the new Loan Agreement and Receivable Assignment Agreement to be finalized and executed on December 18, 2019. Once the contracts are signed, the amount will be released from escrow to the Company. If the Company or its Attorney does not receive a confirmation of such wire transfer by December 16, 2019 and both the new Loan Agreement and Receivable Assignment Agreement are not fully executed and sent back to the Company by the close of business of December 18, 2019, then the Second Tranche will be immediately and unilaterally converted by the Company into equity of the Company at a conversion price of U.S.$0.02 per share as per the terms and conditions of the Original Agreement.
5. This third and final addendum to the June 6, 2018 funding agreement will be duly filed by the Company with the SEC via a respective Form 8-K Current Report.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibits Description
10.1 Third Addendum to June 6, 2018 funding agreement between Xantis S.A. and Argentum 47, Inc.
I feel that they have already begun to execute the "next phase".
The MAXIS GBN deal that was announced on 12/3/19 was a great start.
Although we don't know the full impact it will have on revenue, given MAXIS's reach globally I think it will have a huge impact and will also lead to many more deals.
MAXIS GBN partners with CareClix as latest global wellness provider
Press Release | 12/03/2019
ALEXANDRIA, VA / ACCESSWIRE / December 3, 2019 / Solei Systems Inc (OTC PINK:SOLI) is pleased to announce its partnership with with MAXIS GBN. Following is the press release generated by MAXIS GBN: MAXIS Global Benefits Network (MAXIS GBN) has selected CareClix, a leading telemedicine solutions company, as its global provider of telemedicine services.
As part of the partnership, MAXIS GBN clients will be able to work with CareClix to assist their employees with virtual health access to primary care, specialist care and mental health services. They will be able to take advantage of cost-efficient services to help their employees treat both routine and specialist medical issues. CareClix is one of the third-party suppliers that makes up MAXIS' Global Wellness solution.
Employees are able to access treatment from locally board-certified physicians who speak their language and understand the culture and sensitivities of their market at any time, reducing the time spent waiting for diagnosis and the cost of in-person medical care. Clients of MAXIS GBN are able to give employees access to medical support through CareClix in three ways - mobile apps, on a website or by phone.
Headquartered in Alexandria, VA with an office in Washington, D.C., CareClix's software component was founded by board certified physicians and uses primary care, speciality care, and subspecialty care physicians to deliver expert telemedicine services in almost every field of medicine, clinical care or diagnostics.
Greg Arms, Senior Advisor at CareClix, said: "CareClix is delighted to support MAXIS GBN's multinational clients with our telemedicine platform. Our service uniquely enables individual employees and their families to virtually access - through their handheld devices - the best possible health information and resources available, at any time of the day from anywhere in the world. The proactive use of CareClix telehealth improves personal health and wellness, while also helping employers address the rising cost of medical all over the world."
Dr. Leena Johns, Head of Health and Wellness at MAXIS GBN, said: "We are really excited to partner with CareClix as one of our MAXIS Global Wellness preferred suppliers. Along with our other partners, we really believe we have developed something unique in the market - providing a prescriptive solution to help our multinational clients and their employees address their unique medical and wellness needs where they are not already available locally. By partnering with wellness technology vendors like CareClix, we can help improve employee health and assist multinationals that are looking to address their expensive medical costs."
For media enquiries please contact
Charlotte Pascal / Hugh Fasken
Citigate Dewe Rogerson / +44 (0)20 7025 6400 / maxis@citigatedewerogerson.com
I just let Admin. know that SOLI is still showing it is on the grey market and has a CE on this ihub page
https://ih.advfn.com/stock-market/USOTC/solei-systems-inc-SOLI/stock-price
In the middle of the page it shows
Solei Systems, Inc. (GM CE)
It is managements JOB to work on their business plan:
-acquire telemedicine companies
-negotiate service contracts to generate revenue
-keep up with administrative items.
-communicate with the public
-etc.
Of all the items, I do think that they could do a better job on getting the public informed. But I do think it is on it's way.
The PPS with work itself out along the way.
It was said that SOLI would NEVER raise the money to acquire CareClix. But it did. Then it was said:
-won't complete the CareClix acquisition. But it did.
-won't win the illegal share distribution lawsuit. But it did.
-won't reduce the OS by the 12.6 million illegal shares after winning the
lawsuit. But it did.
-won't find a sponsoring market maker to fill the form to 211 to get off
the greys. But it did.
-won't get the form 211 accepted by FINRA to come off the greys. But it
did.
-won't get the CE removed. But it did.
-then they said that SOLI was delinquent on auditing the CareClix
acquisition. But it wasn't.
-then they said the deal with MAXIS GBN isn't anything because an 8K wasn't
issued ( a PR was issued ). An 8K wasn't required.
-now they are complaining because the OS and Restricted went up, even
though the last 10Q details why & how shares are issued.
SOLI management has been transparent and very professional in all their actions. You can't ask for a more professional management team.
I do believe it is high on their priority list. I do think that it opens up additional doors for them.
SOLI uplisted off the Greys on 11/14. I believe that they can apply to OTCQB 30 days from 11/14 ( which would be next week).
The OTCQB review process is 60-90 days.
Timelines: In most cases the complete listing process will take 60-90 days, although our service providers are very efficient and we are confident that we could have the listing completed within 45-60 days.Feb 24, 2016
And only 6 mill per year are vested. So it will take 4+ years to be full vested.
I just went thru the last 10Q to look at the OS and stock issuance.
Here is what I see:
Today the OS is reported at 170,982,819
As of 9/30/19 the OS was 103,804,390
total difference is: 67,178,429
In the Q in subsequent events:
PP:5,957,002 issued to Private Placement thru 11/19/19 that covered $700k
That leaves $980,000, assuming a conversion of $.1 = 9,800,000 shares more
KB: KB Medical got 2,694,612 in Oct. 2019 for the balance of $900k
Dr. Korangy: starting 10/15 his employment agreement started. He got 24,534,188 shares 30 days after 10/15 ( it takes him a number of years to get fully vested but they should be in the OS as of today).
Dr. K also gets $250,000 in the first year paid all in stock. So two months worth at a conversion rate of $.20 = 208,000
So the total in subsequent events= 43,193,802
I know that there are other little amounts in the Q ( I think Greg Arms gets monthly shares) and my conversion #s could be off a little but that covers a lot of the OS increase.
And that big ask is almost gone. 20k was just bought
I see that. They are not on the bid yet.
Ok thanks!
10k buy at $.30.
Very Nice.
I do think there are games being played.
I am interested to see if the short interest on the OTC Markets page for SOLI changes next week. The last update was on 11/15/2019 and it updates every 30 days IF there is new info.
Agreed. Next news and we are in the $.40s/$.50s
Yes. Just need someone to take out the $.3199 ask.
WOW the big ask (53K) just went away. Only 5700 now
Sold 11 contracts of LK 12/13 $30.5 Naked Puts for $.4618 average.
All gone? There are always yahoos/flippers around. LOL
That is my take also...that they do qualify.
But they have CareClix so that is an advantage by itself.
I just raised the question today because I don't know if SOLI qualifies and if so, if there is any advantage.
(many years ago my father was in the heavy construction business and the company he worked for had a woman as the owner/president. Back then X% of public construction contracts had to go to minority owned construction companies.)
Actually, it's on the list for 12/1/2
12/14/2019 ITXXF Itaconix plc Ordinary Shares Pink Current
12/12/2019 SOLI Solei Systems, Inc. Common Stock Pink Current
12/12/2019 MPNGY Meituan Dianping American Depository Receipts Pink Current
30 from uplist. We uplisted on 11/14